{"id":70759,"date":"2026-05-12T10:48:03","date_gmt":"2026-05-12T10:48:03","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70759"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"survodutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/pt-pt\/product\/survodutide\/","title":{"rendered":"Survodutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Resposta R\u00e1pida \u2014 O que \u00e9 o Survodutide?<\/h3>\n<p style=\"margin: 0;\"><strong>Survodutide<\/strong> (developmental code BI 456906) is a 29-amino-acid long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. In published Phase 2 studies it produced striking effects in MASH (metabolic-dysfunction-associated steatohepatitis) liver fibrosis alongside obesity body-weight reductions of ~19% over 46 weeks. Plasma half-life supports once-weekly dosing. Supplied in 5\u00a0mg and 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>O que obt\u00e9m com a MedsBase:<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/pt-pt\/reviews\/\">de clientes<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Cada encomenda est\u00e1 coberta pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\"><strong>Pol\u00edtica de Garantia de Reenvio<\/strong><\/a> \u2014 se a sua encomenda n\u00e3o chegar no prazo de 20 dias \u00fateis, reenviamo-la.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Especifica\u00e7\u00e3o<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detalhe<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>N\u00famero CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">2230198-02-2 (survodutide; comumente citado)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Tipo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Co-agonista dual de a\u00e7\u00e3o prolongada dos recetores GLP-1\/glucagon (p\u00e9ptido sint\u00e9tico acilado; Boehringer Ingelheim BI 456906; co-desenvolvido com Zealand Pharma)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Peso Molecular<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~3,800 Da (com acila\u00e7\u00e3o de \u00e1cido gordo; forma pept\u00eddica madura)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Estrutura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">29-amino\u00e1cidos sint\u00e9ticos co-agonista pept\u00eddico com substitui\u00e7\u00f5es Aib projetadas para resist\u00eancia \u00e0 DPP-4 e uma cadeia acilada de di\u00e1cido gordo ligada a um res\u00edduo de lisina atrav\u00e9s de um ligador \u03b3-Glu. Substancialmente mais curto do que os co-agonistas derivados da oxintomodulina (mazdutide ~39 aa) enquanto preserva a atividade dual equilibrada nos recetores GLP-1\/glucagom.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forma<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">P\u00f3 liofilizado (branco a branco sujo)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pureza<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599% (HPLC verificado, COA dispon\u00edvel mediante pedido)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Armazenamento<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Liofilizado: 2\u20138 \u00b0C (frigor\u00edfico) para stock de trabalho; \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Reconstitu\u00eddo: 2\u20138 \u00b0C, utilizar no prazo de ~30 dias. Proteger da luz. N\u00e3o congelar-descongelar a solu\u00e7\u00e3o reconstitu\u00edda.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilidade<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u00c1gua bacteriost\u00e1tica (recomendada) ou \u00e1gua est\u00e9ril para janelas de uso mais curtas. Pept\u00eddeos acilados podem dissolver-se mais lentamente \u2014 permita tempo extra de equil\u00edbrio.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>O Que \u00c9 Survodutide?<\/h2>\n<p><strong>Survodutide<\/strong> (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1\/glucagon co-agonist studies programme, alongside the parallel programmes that produced <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">mazdutide<\/a> (Innovent Biologics, China) and the older Pegapamodutide \/ Cotadutide compounds. Survodutide is structurally compact \u2014 just 29 amino acids \u2014 substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation. Survodutide has a mature molecular weight of approximately 3,800\u00a0Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing. The current clinical signature of survodutide is the <strong>efeito impressionante na fibrose hep\u00e1tica MASH (esteato-hepatite associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> reportado no ensaio de Fase 2 \u2014 um resultado que o distinguiu de outros agonistas duplos e triplos com efeitos semelhantes no peso corporal. Os dados de obesidade da Fase 2 mostraram redu\u00e7\u00f5es de peso corporal de aproximadamente 19% com 4,8 mg semanais ao longo de 46 semanas, colocando o survodutide no mesmo n\u00edvel de efeito que o tirzepatide e no limite do agonista triplo retatrutide. O survodutide est\u00e1 atualmente em ensaios de Fase 3 para obesidade (desenho de ensaio do tipo SURMOUNT) e MASH. O survodutide \u00e9 <strong>aprovado<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For the sibling dual GLP-1\/glucagon co-agonist, see our <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> p\u00e1gina de produto; para o agonista triplo que adiciona GIP, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a>. <\/p>\n<h2>Mecanismo de A\u00e7\u00e3o \u2014 Co-Agonismo Duplo do Recetor de GLP-1 \/ Glucagon com \u00canfase Hep\u00e1tica<\/h2>\n<p>O que torna o survodutide mecanicamente distinto entre os p\u00e9ptidos metab\u00f3licos agonistas duplos \u00e9 a <strong>rela\u00e7\u00e3o de pot\u00eancia GLP-1-glucagon relativamente equilibrada<\/strong> que produz tanto efeitos substanciais de gasto energ\u00e9tico (o bra\u00e7o do glucagon) como os efeitos can\u00f3nicos de saciedade\/glic\u00e9micos do GLP-1, com uma \u00eanfase particular nos resultados hep\u00e1ticos:<\/p>\n<ul>\n<li><strong>Ativa\u00e7\u00e3o do receptor GLP-1 \u2014 saciedade, secre\u00e7\u00e3o de insulina pelas c\u00e9lulas \u03b2, esvaziamento g\u00e1strico<\/strong> \u2014 O survodutide ativa o recetor de GLP-1 nas c\u00e9lulas beta pancre\u00e1ticas (secre\u00e7\u00e3o de insulina dependente da glucose, supress\u00e3o do glucagon nas c\u00e9lulas alfa), nos neur\u00f3nios POMC do n\u00facleo arqueado hipotal\u00e2mico (regula\u00e7\u00e3o central do apetite) e nos aferentes vagais g\u00e1stricos (atraso no esvaziamento g\u00e1strico). Este bra\u00e7o sobrep\u00f5e-se ao mecanismo do semaglutide e ao componente GLP-1 de todos os p\u00e9ptidos incret\u00ednicos multi-agonistas.<\/li>\n<li><strong>Ativa\u00e7\u00e3o do recetor de glucagon \u2014 mobiliza\u00e7\u00e3o lip\u00eddica hep\u00e1tica, gasto energ\u00e9tico, ativa\u00e7\u00e3o do tecido adiposo castanho<\/strong> \u2014 A caracter\u00edstica definidora partilhada com <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">mazdutide<\/a> e <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">retatrutide<\/a> is glucagon-receptor agonism. In survodutide studies, this arm produces particularly strong hepatic lipid mobilisation \u2014 hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm&#8217;s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.<\/li>\n<li><strong>Engenharia de equil\u00edbrio de recetores e a rela\u00e7\u00e3o de pot\u00eancia do agonista duplo<\/strong> \u2014 The pharmacological challenge in dual GLP-1\/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation protocols.<\/li>\n<\/ul>\n<p>The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide&#8217;s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical studies. Subcutaneous administration is the standard administration route and the only route used in clinical development. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Survodutide is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>MASLD\/MASH (doen\u00e7a hep\u00e1tica associada \u00e0 disfun\u00e7\u00e3o metab\u00f3lica)<\/strong> \u2014 hepatic triglyceride content, ALT\/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide&#8217;s strongest signal and the basis for its dedicated MASH Phase 3 programme<\/li>\n<li><strong>Obesity and body-composition studies<\/strong> \u2014 modelos pr\u00e9-cl\u00ednicos de roedores com obesidade induzida por dieta (DIO), composi\u00e7\u00e3o corporal (DEXA\/RMN), ensaios de ingest\u00e3o alimentar, medi\u00e7\u00e3o do disp\u00eandio energ\u00e9tico<\/li>\n<li><strong>Type 2 diabetes preclinical studies<\/strong> \u2014 controlo glic\u00e9mico, din\u00e2mica de supress\u00e3o do glucagon, substitutos da HbA1c; o equil\u00edbrio de recetores modificado favorece uma redu\u00e7\u00e3o l\u00edquida da glucose, apesar do componente de glucagon<\/li>\n<li><strong>Energy-expenditure and thermogenesis studies<\/strong> \u2014 disp\u00eandio energ\u00e9tico em repouso, ativa\u00e7\u00e3o do tecido adiposo castanho, express\u00e3o de genes termog\u00e9nicos; particularmente relevante dada a componente de glucagon<\/li>\n<li><strong>Comparative dual-agonist studies<\/strong> \u2014 compara\u00e7\u00e3o direta com o co-agonista alternativo GLP-1\/glucagon <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> (derivado da oxintomodulina, 39 aa), o duplo GLP-1\/GIP <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a>, e o triplo agonista <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a>; receptor-stacking strategy studies<\/li>\n<li><strong>Cardiovascular studies<\/strong> \u2014 efeitos na press\u00e3o arterial, perfis lip\u00eddicos; dados de resultados cardiovasculares acumulados a partir de programas de Fase 2\/3<\/li>\n<li><strong>Farmacologia do eixo do glucagon<\/strong> \u2014 farmacologia isolada do recetor de glucagon, din\u00e2mica da produ\u00e7\u00e3o hep\u00e1tica de glucose, caracteriza\u00e7\u00e3o do equil\u00edbrio de pot\u00eancia entre os recetores de glucagon e GLP-1<\/li>\n<li><strong>Comparative incretin studies<\/strong> \u2014 compara\u00e7\u00e3o com agonista \u00fanico de GLP-1 (<a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a>) e farmacologia combinada do eixo amilina (<a href=\"https:\/\/medsbase.com\/pt-pt\/cagrilintide\/\">Cagrilintide<\/a> + Semaglutide CagriSema).<\/li>\n<\/ul>\n<p>Para um contexto mais amplo sobre onde o survodutide se enquadra na paisagem de pept\u00eddeos metab\u00f3licos multi-agonistas, consulte <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> como o co-agonista duplo de GLP-1\/glucagon irm\u00e3o, <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> como o triplo-agonista que adiciona GIP, <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> como a alternativa dupla que utiliza GIP em vez de glucagon, e <a href=\"https:\/\/medsbase.com\/pt-pt\/semaglutide\/\">Semaglutide<\/a> como a linha de base de agonista \u00fanico. Navegue pelo <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\">cat\u00e1logo de p\u00e9ptidos<\/a> para encontrar compostos relacionados. <\/p>\n<h2>For\u00e7as e Concentra\u00e7\u00f5es Dispon\u00edveis<\/h2>\n<p>MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical protocol lengths. Each strength is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">For\u00e7a do frasco<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Caso de uso t\u00edpico<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tamanhos das embalagens<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 pilot dosing, single-cohort protocols, titration arms<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Protocolos de ciclo prolongado, estudos de m\u00faltiplas coortes, menor custo por mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 frascos<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3\u20134.8\u00a0mg weekly with a 4\u20136 month titration schedule, so pharmaceutical-grade vials at 5\u00a0mg or 10\u00a0mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides. <\/p>\n<h2>Compara\u00e7\u00e3o \u2014 Survodutide vs Mazdutide<\/h2>\n<p>O Survodutide e o <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> are the two principal dual GLP-1 \/ glucagon co-agonist peptides in current literature. They share receptor pharmacology \u2014 both activate the GLP-1 and glucagon receptors, both lack GIP activity \u2014 but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e9rio<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Survodutide<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Mazdutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Perfil de recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (duplo)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + glucagon (duplo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Comprimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">29 amino\u00e1cidos (compacto)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~39 amino\u00e1cidos (derivado da oxintomodulina)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Desenvolvedor<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Boehringer Ingelheim + Zealand Pharma<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Innovent Biologics (licenciado da Eli Lilly)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>C\u00f3digo de desenvolvimento<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">BI 456906<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IBI362 \/ LY3305677<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Equil\u00edbrio de recetores<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Favor\u00e1vel ao glucagon (fortes efeitos hep\u00e1ticos)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 preferido (perfil glic\u00e9mico mais limpo)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Meia-vida<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dias (semanal)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Semanal (acilado)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Sinal cl\u00ednico distintivo<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Melhoria da fibrose hep\u00e1tica MASH (Fase 2)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Primeiro agonista duplo aprovado (China NMPA)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Efeito no peso corporal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~19% (Fase 2, 46 semanas)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~15\u201317% (Fase 3, 48 semanas)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typical studies weekly dose<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">0,3\u20134,8 mg<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">4\u20139\u00a0mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For MASH\/MASLD liver-disease studies, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For studies interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide&#8217;s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1\/glucagon co-agonist pharmacology \u2014 both are likely to remain in active studies and clinical development through this decade. <\/p>\n<h2>Armazenamento e Reconstitui\u00e7\u00e3o<\/h2>\n<p><strong>Antes da reconstitui\u00e7\u00e3o:<\/strong> armazene frascos liofilizados refrigerados a 2\u20138\u00a0\u00b0C na embalagem original para estoque de trabalho de curto prazo. Para armazenamento de longo prazo n\u00e3o aberto, congele a \u221220\u00a0\u00b0C. O survodutide liofilizado \u00e9 est\u00e1vel sob refrigera\u00e7\u00e3o por at\u00e9 24 meses e a \u221220\u00a0\u00b0C por at\u00e9 36 meses. Evite ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o no p\u00f3 liofilizado. <strong>Procedimento de reconstitui\u00e7\u00e3o:<\/strong> inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5\u00a0mg vial, 2.0\u00a0mL of bacteriostatic water yields a 2.5\u00a0mg\/mL working concentration \u2014 0.04\u00a0mL delivers 100\u00a0mcg; 0.2\u00a0mL delivers 500\u00a0mcg; ~1.9\u00a0mL delivers a 4.8\u00a0mg clinical-equivalent dose. Swirl gently \u2014 do <strong>n\u00e3o<\/strong> sacuda \u2014 e permita 5\u201310 minutos para dissolu\u00e7\u00e3o completa (pept\u00eddeos acilados dissolvem-se mais lentamente do que pept\u00eddeos menores n\u00e3o modificados). Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda deve ser clara e incolor, sem part\u00edculas vis\u00edveis. <strong>Ap\u00f3s reconstitui\u00e7\u00e3o:<\/strong> armazene refrigerado a 2\u20138\u00a0\u00b0C e utilize dentro de 30 dias para estabilidade \u00f3tima. N\u00e3o congele a solu\u00e7\u00e3o reconstitu\u00edda \u2014 ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam a integridade do p\u00e9ptido. Descarte qualquer frasco que apresente turva\u00e7\u00e3o, precipitado ou descolora\u00e7\u00e3o. <\/p>\n<h2 id=\"faqs\">Perguntas Frequentes<\/h2>\n<h3>What is Survodutide used for in studies?<\/h3>\n<p>Survodutide is used in studies investigating MASLD\/MASH liver disease (its strongest distinctive signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1\/GIP (tirzepatide), the sibling dual GLP-1\/glucagon mazdutide, and triple-agonist retatrutide. The pharmaceutical-grade survodutide sold here is <strong>n\u00e3o<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>Como o Survodutide difere do Mazdutide?<\/h3>\n<p>Both are dual GLP-1\/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH studies, survodutide is the canonical choice; for clean glycaemic-axis studies with minimal glucagon interference, mazdutide is preferred. <\/p>\n<h3>Como o Survodutide difere do Tirzepatide?<\/h3>\n<p>Ambos s\u00e3o agonistas duplos de incretina, mas ativam diferentes segundos recetores. O Tirzepatide \u00e9 GLP-1 + GIP (~22% de efeito no peso corporal no SURMOUNT-1). O Survodutide \u00e9 GLP-1 + glucagon (~19% na Fase 2). As duas combina\u00e7\u00f5es de recetores produzem perfis metab\u00f3licos qualitativamente diferentes: o GIP adiciona lip\u00f3lise de adip\u00f3citos em condi\u00e7\u00f5es de jejum; o glucagon adiciona gasto energ\u00e9tico substancial e mobiliza\u00e7\u00e3o lip\u00eddica hep\u00e1tica. O Survodutide tem o sinal \u00fanico de fibrose MASH devido ao seu efeito lip\u00eddico hep\u00e1tico impulsionado pelo glucagon. <\/p>\n<h3>Como o Survodutide difere do Retatrutide?<\/h3>\n<p>Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon \u2014 it is a triple agonist. Survodutide stops at the dual combination. Retatrutide&#8217;s Phase 2 body-weight effect (~24%) is larger than survodutide&#8217;s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For studies isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools. <\/p>\n<h3>What is the typical Survodutide dose?<\/h3>\n<p>Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3\u00a0mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8\u00a0mg weekly over approximately 24 weeks. A 5\u00a0mg vial reconstituted with 2.0\u00a0mL bacteriostatic water yields 2.5\u00a0mg\/mL \u2014 ~1.9\u00a0mL equals a 4.8\u00a0mg clinical-equivalent dose. <\/p>\n<h3>O Survodutide est\u00e1 aprovado pela FDA?<\/h3>\n<p>No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. <\/p>\n<h3>Como deve ser armazenado o Survodutide?<\/h3>\n<p>Frascos liofilizados: refrigerados a 2\u20138 \u00b0C para stock de trabalho a curto prazo, ou \u221220 \u00b0C para armazenamento a longo prazo de frascos n\u00e3o abertos. Solu\u00e7\u00e3o reconstitu\u00edda: refrigerada a 2\u20138 \u00b0C, utilizar no prazo de 30 dias. N\u00e3o congelar a solu\u00e7\u00e3o reconstitu\u00edda \u2014 os ciclos de congela\u00e7\u00e3o-descongela\u00e7\u00e3o degradam o p\u00e9ptido. Proteger da luz direta em todos os momentos. <\/p>\n<h3>Como devo reconstituir o Survodutide?<\/h3>\n<p>Siga o procedimento de reconstitui\u00e7\u00e3o acima. Adicione \u00e1gua bacteriost\u00e1tica pela parede lateral do frasco (n\u00e3o diretamente sobre o p\u00f3 liofilizado), agite suavemente e deixe repousar durante 5\u201310 minutos para dissolu\u00e7\u00e3o completa (os p\u00e9ptidos acilados dissolvem-se mais lentamente do que os p\u00e9ptidos menores n\u00e3o modificados). N\u00e3o <strong>n\u00e3o<\/strong> Agite o frasco. Uma solu\u00e7\u00e3o corretamente reconstitu\u00edda \u00e9 clara e incolor. Para um frasco de 5\u00a0mg + 2,0\u00a0mL de diluente, a concentra\u00e7\u00e3o de trabalho \u00e9 de 2,5\u00a0mg\/mL. <\/p>\n<h3>Que dosagens est\u00e3o dispon\u00edveis na MedsBase?<\/h3>\n<p>MedsBase carries Survodutide in 5\u00a0mg and 10\u00a0mg lyophilized vials. Each strength is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Why is Survodutide particularly relevant for MASH studies?<\/h3>\n<p>Survodutide&#8217;s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published studies. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm&#8217;s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial \u2014 an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects. <\/p>\n<h3>O componente glucagon causa hiperglicemia?<\/h3>\n<p>O cl\u00e1ssico \u201cparadoxo do glucagon\u201d aplica-se ao Survodutide, tal como a outros co-agonistas GLP-1\/glucagon: o glucagon isoladamente aumenta a glucose ao estimular a produ\u00e7\u00e3o hep\u00e1tica de glucose, mas a a\u00e7\u00e3o dominante de redu\u00e7\u00e3o da glucose do componente GLP-1 sobre a insulina e a supress\u00e3o do glucagon nas c\u00e9lulas beta e alfa sobrep\u00f5e-se a este efeito. A propor\u00e7\u00e3o de equil\u00edbrio recetor projetada do Survodutide alcan\u00e7a uma redu\u00e7\u00e3o l\u00edquida da glucose apesar da ativa\u00e7\u00e3o do recetor de glucagon \u2014 os dados publicados da Fase 2 confirmam o melhor controlo glic\u00e9mico em coortes de DM2 na dose de manuten\u00e7\u00e3o. <\/p>\n<h3>Does Survodutide cause side reported effects?<\/h3>\n<p>O achado mais consistente \u00e9 gastrointestinal, semelhante a outros pept\u00eddeos do eixo GLP-1 \u2014 n\u00e1useas, supress\u00e3o transit\u00f3ria do apetite e esvaziamento g\u00e1strico retardado s\u00e3o dose-dependentes e tendem a atenuar-se com o longo esquema de titula\u00e7\u00e3o utilizado na Fase 2. Os achados relacionados com o componente glucagon incluem eleva\u00e7\u00f5es modestas na frequ\u00eancia card\u00edaca em repouso e (raramente) efeitos transit\u00f3rios na press\u00e3o arterial. A longa titula\u00e7\u00e3o \u00e9 parcialmente concebida para minimizar estes efeitos. <\/p>\n<h3>Qual \u00e9 a meia-vida do Survodutide?<\/h3>\n<p>In preclinical and clinical studies, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue. <\/p>\n<h3>How long does Survodutide take to show effects in preclinical studies?<\/h3>\n<p>Os efeitos farmacodin\u00e2micos agudos na toler\u00e2ncia \u00e0 glucose e no esvaziamento g\u00e1strico s\u00e3o detet\u00e1veis poucas horas ap\u00f3s a primeira dose. Os efeitos no peso corporal em modelos de roedores DIO tornam-se tipicamente estatisticamente significativos ap\u00f3s 1\u20132 semanas de administra\u00e7\u00e3o semanal. Os efeitos em MASLD\/MASH no conte\u00fado hep\u00e1tico de triglic\u00e9ridos e na normaliza\u00e7\u00e3o de ALT\/AST acumulam-se ao longo de 8\u201316 semanas de administra\u00e7\u00e3o regular. O efeito m\u00e1ximo na composi\u00e7\u00e3o corporal desenvolve-se ao longo de 24\u201346 semanas, refletindo a trajet\u00f3ria da Fase 2. <\/p>\n<h3>Posso encomendar Survodutide para envio internacional?<\/h3>\n<p>Sim. A MedsBase envia Survodutide para todo o mundo a partir da nossa rede dedicada de envio de p\u00e9ptidos. As encomendas exclusivas de p\u00e9ptidos qualificam-se para o nosso servi\u00e7o de envio de p\u00e9ptidos aut\u00f3nomo. Todas as encomendas s\u00e3o enviadas em embalagens com controlo de temperatura, com rastreio completo e est\u00e3o cobertas pela nossa <a href=\"https:\/\/medsbase.com\/pt-pt\/medsbase-re-shipment-assurance-policy\/\">Pol\u00edtica de Garantia de Reenvio<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Metabolic, MASH, and Multi-Agonist Studies<\/h2>\n<ul>\n<li><a href=\"\/pt-pt\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 Co-agonista duplo GLP-1\/glucagon irm\u00e3o \u2014 propor\u00e7\u00e3o alternativa de equil\u00edbrio de recetores<\/li>\n<li><a href=\"\/pt-pt\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Agonista triplo GLP-1\/GIP\/glucagon \u2014 adiciona GIP ao perfil duplo GLP-1\/glucagon<\/li>\n<li><a href=\"\/pt-pt\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Agonista duplo GLP-1\/GIP \u2014 agonista duplo alternativo utilizando GIP em vez de glucagon<\/li>\n<li><a href=\"\/pt-pt\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Agonista \u00fanico GLP-1 \u2014 comparador de base can\u00f3nico<\/li>\n<li><a href=\"\/pt-pt\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 An\u00e1logo de amilina \u2014 abordagem alternativa de farmacologia combinada<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Leitura Adicional<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore o panorama do co-agonista duplo GLP-1\/glucagon<\/strong><\/p>\n<p style=\"margin: 0;\">Explore a gama completa <a href=\"https:\/\/medsbase.com\/pt-pt\/peptides\/\"><strong>cat\u00e1logo de p\u00e9ptidos<\/strong><\/a>, com compostos multi-agonistas relacionados, incluindo <a href=\"https:\/\/medsbase.com\/pt-pt\/mazdutide\/\">Mazdutide<\/a> (agonista duplo GLP-1\/glucagon), <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide\/\">Retatrutide<\/a> (triplo-agonista), e <a href=\"https:\/\/medsbase.com\/pt-pt\/tirzepatide\/\">Tirzepatide<\/a> (agonista duplo GLP-1\/GIP). Guia comparativo: <a href=\"https:\/\/medsbase.com\/pt-pt\/retatrutide-vs-tirzepatide\/\">Retatrutida vs Tirzepatida \u2014 agonista triplo vs agonista duplo<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Coagonista dual de recetores de GLP-1 + glucagon<br \/>\n\u2705 P\u00e9ptido compacto de 29-aa da Boehringer\/Zealand (BI 456906)<br \/>\n\u2705 Forte sinal de fibrose hep\u00e1tica MASH na Fase 2<br \/>\n\u2705 Equil\u00edbrio de recetores favorecido pelo glucagon<br \/>\n\u2705 Dosagem semanal (~6 dias de meia-vida)<\/p>\n<p><strong>Survodutide<\/strong> cont\u00e9m composto de p\u00e9ptido sint\u00e9tico.<\/p>","protected":false},"featured_media":70984,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5441,6286],"class_list":["post-70759","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-peptide","product_tag-survodutide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product\/70759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=70759"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media\/70984"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=70759"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_brand?post=70759"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_cat?post=70759"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/pt-pt\/wp-json\/wp\/v2\/product_tag?post=70759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}